3 recruiting, 2 completed, 1 active not recruiting, 1 not yet recruiting. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 3, Completed 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow Solid Cancer: new trials by email Literature Review of Solid Cancer trials Research Report on Solid Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors SI-B036 - Urological Cancer, Solid Cancer | Phase 1 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 30 | 2026-08-01 | 2026-08-26 |
| A Study of AK138D1 in Advanced Malignant Tumors AK138D1 - Solid Cancer | Phase 1 | Recruiting | Akeso | 200 | 2025-10-22 | 2025-12-15 |
| Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors HCB101, Trastuzumab, Pertuzumab - Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | FBD Biologics Limited | 500 | 2025-03-13 | 2026-02-04 |
| A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors AK138D1 - Solid Cancer | Phase 1 | Recruiting | Akeso | 100 | 2025-02-24 | 2025-03-06 |
| A Study of HS-20124 in Patients with Advanced Solid Tumors HS-20124 (Phase Iaļ¼Dose escalation ), HS-20124 (Phase Ib: Dose expansion) - Solid Cancer | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 450 | 2024-10-30 | 2025-01-08 |
| Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months - Solid Cancer | Phase 1 / Phase 2 | Terminated | Oncovir, Inc. | 7 | 2018-09-25 | 2021-02-01 |
| Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes) TSA-CTL, Cyclophosphamide, Fludarabine - Solid Cancer | Phase 1 | Completed | BGI, China | 11 | 2016-12-22 | 2023-02-02 |
| A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer cabazitaxel (XRP6258) - Solid Cancer | Phase 1 | Completed | Sanofi | 76 | 2009-06-01 | 2013-05-16 |
Colorectal Neoplasms (1) · Melanoma (1) · Urologic Neoplasms (1)
Neoplasms (2) · Neoplasms by Site (2) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Male Urogenital Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1)
atezolizumab (2) · pembrolizumab (2) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Capecitabine (1) · Carboplatin (1) · Cetuximab (1) · Cyclophosphamide (1) · Etoposide (1) · Fluorouracil (1) · Irinotecan (1) · Leucovorin (1) · Nivolumab (1) · Oxaliplatin (1) · Paclitaxel (1)
Akeso (2) · BGI, China (1) · FBD Biologics Limited (1) · Hansoh BioMedical R&D Company (1) · Oncovir, Inc. (1) · Sanofi (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1)
China (5) · United States (2) · Australia (1)
David H Smith, MD (1) · Frederick P Smith, MD (1) · Nina Bhardwaj, MD, PhD (1) · Wenting Li, MD (1) · Xiao Sh Zhang, Doctor (1)
PMID 14639532, PMID 20697067, PMID 22065672, PMID 24812403, PMID 25117475, PMID 25837513, PMID 27312342, PMID 37301885